The Exosome-Based Therapeutic market is experiencing growth as the focus on the use of advanced biologicals that have the potential to facilitate regenerative medicine and delivery of therapy intensifies. Exosomes, which belong to a category of extracellular vesicles, are becoming a subject of research in the field of cell-free therapeutic development owing to several advantages associated with their use over traditional cell-based methods, such as reduced immune reactions and targeted delivery capacity, among others.
The market size of the Exosome-Based Therapy Market stood at USD 54.08 million in 2025 and is forecast to touch USD 288.10 million by 2035 at a CAGR of 18.22% from 2026-2035. The major factors that have led to an upsurge in the market include increased adoption of cell-free therapeutics platforms, growing clinical research activities, advancements in engineered exosomes, and increasing applications in oncology, neurodegenerative diseases, and regenerative medicine.
Gain Actionable Intelligence on the Exosome-Based Therapy Market – Request a Sample Report
Exosome-Based Therapy Market Key Players
Major companies operating in the global Exosome-Based Therapy Market include Codiak BioSciences, Evox Therapeutics, Capricor Therapeutics, Exopharm, Aegle Therapeutics, ThermoGenesis / Thermo Fisher Scientific, ReNeuron, Kimera Labs, Vesigen Therapeutics, Eternal Labs, ExoCoBio, Anjarium Biosciences, Avidity Biosciences, PureTech Health, Celularity, Exogenus Therapeutics, Aruna Bio, Evoxplore Therapeutics, Hansa Biopharma, Exostem Bio, and other emerging biotechnology providers.
Strategic Developments & Industry Innovations
- March 2025: Codiak BioSciences made a move by advancing its exoIL-12 platform to Phase II oncology clinical trials, showing how powerful the engineering of exosomes is for cancer treatment.
- February 2025: Evox Therapeutics announced encouraging preclinical findings of its exosome-based delivery of RNA therapeutics targeting the central nervous system, thus facilitating the progress of its pipeline in neurodegenerative diseases.
- Increasingly, exosome technology developers have been concentrating on engineering platforms that deliver RNA and other payloads in a targeted manner.
- TeManufacturing, purification and quality control processes are improving in consistency and commercial viability due to technological improvements.
- InIncreasing collaborations between biotech firms and institutions of academia are fast-tracking clinical research, therapy development and regulation.
Key Players Driving Innovation in Exosome-Based Therapy Market
Codiak BioSciences
Pioneering Engineered Exosome Therapeutics Codiak Biosciences is a biotech company that is working on engineered exosome therapies to deliver medicines to particular cells and tissues.The company leverages exosome platforms to deliver RNA, proteins and other forms of drugs.
In March 2025, Codiak Biosciences’ exoIL-12 platform entered Phase II clinical trials in oncology. This demonstrates the increasing possibility of using exosomes as a technology for the delivery of therapies.
Evox Therapeutics: Exosome engineering for targeted delivery of RNA therapeutics
Evox Therapeutics is a biotech firm that has gained credibility in the development of exosome therapeutics using RNA for precision medicine, especially in rare diseases. Exosome engineering and manufacturing capabilities are used by the firm to enhance stability, targeting and payload delivery.
February 2025 saw Evox Therapeutics announce encouraging preclinical results regarding the exosome engineering platform developed by the firm to deliver RNA-based therapies to the brain. The development is aiding the development pipeline of Evox Therapeutics in the field of neurological diseases and neurodegeneration.
How the Exosome-Based Therapy Market Is Transforming Advanced Therapeutic Development
Exosome-Based Therapy Market has revolutionized the field of advanced biologics in terms of being a cell-free method of therapeutic delivery. Exosomes have natural capabilities of delivering proteins, RNA, and other biological molecules within the body; hence, they make good candidates for the targeted delivery of drugs. There are a lot of prospects with regards to minimal immune response, biological stability, and targeted delivery, hence increased investment in this field.
Engineering exosomes is another trend which makes the industry grow. The work is in progress to develop the technology of delivering specific cargo using engineered exosomes and targeting pathogenic tissue selectively. Thus, there appear prospects for the utilization of engineering exosomes in oncology, neurology, regenerative medicine, and many others.
North America continues to be the dominating region in the global Exosome-Based Therapy Market with 44% market share in the global Exosome-Based Therapy market. The region enjoys an advantage of having a flourishing biotech industry, robust clinical research activities, high investments in R&D, and key players in the development of exosome-based therapies. Europe follows North America and occupies a significant market position due to its high level of academic research, clinical trials, and biotech infrastructure. On the other hand, APAC is experiencing rapid growth in the market.
With further developments in exosome technology, manufacturing, delivery and clinical testing, Exosome-Based Therapy Market will continue to be an essential area of innovation in advanced biological therapeutics and next-generation therapy development.
